Navigation Links
Volcano Announces Upcoming Data Presentations from Large-Scale Studies on Physiology and Imaging Technologies at TCT 2013
Date:10/27/2013

013 reflect the evolution of our significant investment in clinical science over the last several years, and will help guide physicians in making important patient care decisions. With the approval of our iFR modality in Europe and Japan and the U.S. launch of the new Verrata™ Pressure Guide Wire, our goal is to further simplify workflows so that these advanced technologies become a faster, simpler and more routine part of everyday practice and can benefit more patients."

Volcano will display its products and technologies at Booth 1104, Exhibit H., including three new launches:

  • Verrata™ Pressure Guide Wire,
  • Crux® Vena Cava Filter, and
  • iFR® modality (CE Mark countries and Japan only).

The company will also host a Breakfast Symposium that will showcase data from ADVISE II and the ADAPT-DES IVUS analysis, and review the upcoming SYNTAX II study. Specific details follow.

Key Presentations in the Scientific Program

Tuesday, October 29, 1:15 p.m.
Does IVUS Reduce Stent Thrombosis with DES? Two-Year Results from the Prospective, Multicenter ADAPT-DES Study
Presented by Akiko Maehara, M.D.
Moscone West, 2nd Floor, Room 2010

Wednesday, October 30, 1:54 - 2:06 p.m.
A Prospective, Registry Evaluation of iFR vs. FFR: ADVISE II*
Presented by Javier Escaned, M.D., Ph.D.
Moscone North, Lower Level, Hall D, Coronary Theater
*First Report Investigation

Volcano-Sponsored Breakfast Symposium

Putting Appropriateness Within Reach: New Global Clinical Data and Workflows
Thursday, October 31
The Moscone Center, Moscone North, Lower Level, Room 132

7:00 a.m.
State of the Union on Global PCI Guidelines Today and Where to Expand in the Fu
'/>"/>

SOURCE Volcano Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
2. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
3. Volcano Corporation Presentation At Jefferies Conference To Be Webcast
4. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
5. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
7. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
8. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
9. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
10. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
11. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015   Regulus Therapeutics ... leading the discovery and development of innovative medicines targeting ... and highlights for the quarter ended March 31, 2015 ... markets close. Regulus will host a ... at 5:00 pm Eastern Daylight Time to discuss its ...
(Date:4/30/2015)... (Nasdaq: NKTR ) today reported its financial results ... Cash and investments in marketable securities at ... $262.8 million at December 31, 2014. Our cash and ... a $100.0 million milestone payment received from AstraZeneca in ... in the U.S. "The recent U.S. launch ...
(Date:4/30/2015)... CARLSBAD, Calif. , April 30, 2015 /PRNewswire/ ... today it has earned a $10 million milestone ... an undisclosed target to treat a neurological disorder.  ... includes four drugs in development, under Isis, and ... novel therapies to treat neurological and neuromuscular disorders.  ...
Breaking Medicine Technology:Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 2Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 3Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 4Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 5Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 6Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 7Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 8Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 9Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 10Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 11Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 12Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen 2Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen 3
... BOSTON, Nov. 2 Schering-Plough Corporation (NYSE: SGP ... Phase IIa study of narlaprevir (SCH 900518), its investigational, ... patients with chronic hepatitis C virus (HCV) genotype 1. ... which patients received a 4-week lead-in of PEGINTRON(R) (peginterferon ...
... HCA has announced that Richard M. Bracken will become chairman ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20050825/CLTH069LOGO ) ... who will retire from the company, effective that same date. ... executive vice president, was elected to the board of directors, ...
Cached Medicine Technology:Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 2Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 4Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 5Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 6Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 7Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 8Bracken to Become Chairman of HCA's Board of Directors Effective Dec. 15 2
(Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch ... latest and coolest technology products available to consumers. Scott Steinberg, ... review and shared with viewers how to protect their private ... is on computers and even more so online. It helps ... all over the world. In terms of work, the internet ...
(Date:5/3/2015)... 03, 2015 It is not too late to ... Walk in Memory of Lissa Anne Been in Arnold, Missouri ... great family-friendly event to honor her loving memory. It has benefited ... , Just having turned 37, Lissa suffered a brain aneurysm ... August 24, 2012. This event is designed to serve as a ...
(Date:5/2/2015)... 2015 Vancouver fencing company, QS Fencing, has ... advice to prospective clients related to their questions on railings ... railings around their decks and patios. While that seems like ... up once the person rolls up their sleeve to start ... railing in finding a gate that matches it. , Instead ...
(Date:5/2/2015)... We are pleased to announce the ... as one of the Top Workplaces of 2015. , ... treatment field for their ethics and standards of excellence. ... continue their educational efforts. The Delray Recovery Center prides ... their purpose – to help individuals heal from the ...
(Date:5/2/2015)... 2015 As a nonsurgical staple ... the face, neck and décolleté, radiofrequency energy is ... potential for the success of vulvovaginal rejuvenation. In ... Advisory Council, ThermiGyn’s Women’s Health Clinical Advisory Board ... that ThermiGyn’s temperature controlled radio frequency, specifically that ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3
... Pharmaceuticals Inc. today,announced the appointment of Anthony "Tony" ... the recently initiated Phase 2 clinical trial of,CTS-1027 ... assisting in the,development of the longer-term clinical development ... more than 20 years in the,industry. Previous industrial ...
... Massey Cancer Center will open a Phase I ... with leading researchers from Israel, marking the first ... their counterparts in Israel. , The study ... U.S.-Israel Bi-National Industrial Research and Development Foundation (BIRDF). ...
... A free white paper is helping,building owners ... can result when they,re forced by the construction,schedule ... "system final,completion.", "There,s a disturbing trend in ... after occupancy," says Mike Della Barba,Director of Commissioning ...
... Social Security at http://www.nasi.org , WASHINGTON, March ... to comment on the implications of the,2008 Social Security ... listed below are members of the National Academy,of Social ... up of the nation,s leading,experts on Social Security, Medicare, ...
... Healthy,Coffee USA, Inc., the marketing arm of ... that Jim Clayton, a multi-level,marketing expert and start-up ... consultant. Mr. Clayton brings to the company a ... Clayton is a,start-up specialist who has been engaged ...
... of dying increased for patients with the common condition, ... Older people with heart failure face heightened odds of ... largest study ever conducted on the issue. , "We,re ... lead researcher Dr. Adrian F. Hernandez, an assistant professor ...
Cached Medicine News:Health News:Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer 2Health News:VCU Massey Cancer Center to partner with Israeli biotech firm 2Health News:VCU Massey Cancer Center to partner with Israeli biotech firm 3Health News:White Paper Helps Building Owners Avoid Costs, Downfalls of Construction Projects 2Health News:NASI Experts Available to Comment on 2008 Social Security and Medicare Trustees Reports 2Health News:NASI Experts Available to Comment on 2008 Social Security and Medicare Trustees Reports 3Health News:MLM Expert and Start-Up Specialist Jim Clayton Joins Healthy Coffee USA 2Health News:MLM Expert and Start-Up Specialist Jim Clayton Joins Healthy Coffee USA 3Health News:Heart Failure Raises Risks After Non-Cardiac Surgeries 2Health News:Heart Failure Raises Risks After Non-Cardiac Surgeries 3
... accurate portable, waterproof system for pH, mV (ORP), ... results can be obtained when used with a ... This GLP/GMP compliant system includes an RS-232 interface ... Up to 100 data sets can be stored ...
... 3 swing doors, 12 shelves. Over-sized compressor. ... Fluorescent interior lighting. Self-Contained System No plumbing ... Full One Year Warranty on Parts & ... Compressor. Also available as a chromatography ...
... shelves.Over-sized compressor. Triple pane thermal glass. ... System No plumbing required. Equipped with a ... on Parts & Labor and an Additional 4 ... as a chromatography unit which includes two access ...
... 1 swing door 4 shelves. ... Self-closing doors. Fluorescent interior lighting. Self-Contained ... 9 foot cord. Full One Year Warranty ... Year Warranty on Compressor. Also available ...
Medicine Products: